GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SynAct Pharma AB (OSTO:SYNACT) » Definitions » Total Long-Term Liabilities

SynAct Pharma AB (OSTO:SYNACT) Total Long-Term Liabilities : kr31.61 Mil (As of Sep. 2024)


View and export this data going back to 2016. Start your Free Trial

What is SynAct Pharma AB Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. SynAct Pharma AB's Total Long-Term Liabilities for the quarter that ended in Sep. 2024 was kr31.61 Mil.

SynAct Pharma AB Total Long-Term Liabilities Historical Data

The historical data trend for SynAct Pharma AB's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SynAct Pharma AB Total Long-Term Liabilities Chart

SynAct Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Long-Term Liabilities
Get a 7-Day Free Trial - - 2.11 1.06 26.89

SynAct Pharma AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.02 26.89 33.87 32.94 31.61

SynAct Pharma AB Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

SynAct Pharma AB Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of SynAct Pharma AB's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

SynAct Pharma AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SynAct Pharma AB (OSTO:SYNACT) » Definitions » Total Long-Term Liabilities
Comparable Companies
XSAT:CURAS OSTO:XBRANE OSTO:CANTA OSTO:ITECH OSTO:DMYD B OSTO:INIT OSTO:ONCO OSTO:IVACC OSTO:INDEX OSTO:KDEV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
8F8:Germany
Address
Sheelevagen 2, Lund, SWE, 223 81
Website
https://www.synactpharma.se
SynAct Pharma AB is a clinical-stage biotech company focused on resolving inflammation through selective activation of the melanocortin system. The company has a platform technology based on a new class of drug candidates that target acute exacerbations in chronic inflammatory diseases with the primary aim of stimulating natural healing mechanisms. AP1189, the company's lead drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.

SynAct Pharma AB Headlines

No Headlines